Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Payables (2016 - 2025)

Immucell (ICCC) has disclosed Payables for 16 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables rose 165.0% year-over-year to $2.3 million, compared with a TTM value of $2.3 million through Sep 2025, up 165.0%, and an annual FY2024 reading of $934883.0, up 367.44% over the prior year.
  • Payables was $2.3 million for Q3 2025 at Immucell, up from $420139.0 in the prior quarter.
  • Across five years, Payables topped out at $2.3 million in Q3 2025 and bottomed at $138040.0 in Q1 2023.
  • Average Payables over 5 years is $1.1 million, with a median of $876836.0 recorded in 2024.
  • The sharpest move saw Payables crashed 90.9% in 2023, then surged 1452.35% in 2024.
  • Year by year, Payables stood at $726781.0 in 2021, then dropped by 0.01% to $726736.0 in 2022, then tumbled by 72.48% to $200000.0 in 2023, then soared by 367.44% to $934883.0 in 2024, then skyrocketed by 148.55% to $2.3 million in 2025.
  • Business Quant data shows Payables for ICCC at $2.3 million in Q3 2025, $420139.0 in Q2 2025, and $2.0 million in Q1 2025.